Prelude Therapeutics Incorporated Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q2 2024 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q3 2024 | 3 | -$0.48 | -$0.46 | -$0.47 |
| Q1 2025 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q2 2025 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q3 2025 | 1 | -$0.44 | -$0.44 | -$0.44 |
| Q4 2025 | 1 | -$0.44 | -$0.44 | -$0.44 |
Prelude Therapeutics Incorporated Earnings Date And Information
Prelude Therapeutics Incorporated last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.43 earnings per share for the quarter, topping analysts' consensus estimates of $-0.48 by $0.05. The company had revenue of 3.00 M for the quarter and had revenue of 0 for the year. Prelude Therapeutics Incorporated has generated $-2 earnings per share over the last year ($-2.02 diluted earnings per share) and currently has a price-to-earnings ratio of -0.55. Prelude Therapeutics Incorporated has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Prelude Therapeutics Incorporated Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.48 | -$0.43 | 0.05 | $3.00 M | $3.00 M |
| 08/12/2024 | Q2 2024 | -$0.46 | -$0.46 | 0 | $0 | $0 |
| 05/07/2024 | Q1 2024 | -$0.47 | -$0.42 | 0.05 | $0 | |
| 02/15/2024 | Q4 2023 | -$0.50 | -$0.48 | 0.02 | $3.42 M | |
| 11/01/2023 | Q3 2023 | -$0.58 | -$0.45 | 0.13 | $0 | |
| 08/03/2023 | Q2 2023 | -$0.65 | -$0.54 | 0.11 | $0 | |
| 05/08/2023 | Q1 2023 | -$0.68 | -$0.55 | 0.13 | $0 | |
| 03/15/2023 | Q4 2022 | -$0.63 | -$0.44 | 0.19 | $0 | |
| 11/14/2022 | Q3 2022 | -$0.63 | -$0.62 | 0.01 | $0 | |
| 08/09/2022 | Q2 2022 | -$0.60 | -$0.53 | 0.07 | $0 | |
| 05/10/2022 | Q1 2022 | -$0.68 | -$0.61 | 0.07 | $0 | |
| 03/17/2022 | Q4 2021 | -$0.71 | $0 | |||
| 11/12/2021 | Q3 2021 | -$0.62 | -$0.66 | -0.04 | $0 | |
| 08/12/2021 | Q2 2021 | -$0.51 | -$0.58 | -0.07 | $0 | |
| 05/11/2021 | Q1 2021 | -$0.41 | -$0.47 | -0.06 | $0 | |
| 03/16/2021 | Q4 2020 | -$0.47 | -$0.51 | -0.04 | $0 | |
| 11/10/2020 | Q3 2020 | -$0.43 | -$0.44 | -0.01 | $0 | |
| 06/29/2020 | Q2 2020 | -$0.30 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.29 | $0 | |||
| 12/30/2019 | Q4 2019 | -$0.31 | $0 |
Prelude Therapeutics Incorporated Earnings: Frequently Asked Questions
-
When is Prelude Therapeutics Incorporated's earnings date?
Prelude Therapeutics Incorporated has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
-
Did Prelude Therapeutics Incorporated beat their earnings estimates last quarter?
In the previous quarter, Prelude Therapeutics Incorporated (:PRLD) reported $-0.43 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.48 by $0.05.
-
How can I listen to Prelude Therapeutics Incorporated's earnings conference call?
The conference call for Prelude Therapeutics Incorporated's latest earnings report can be listened to online.
-
How can I read Prelude Therapeutics Incorporated's conference call transcript?
The conference call transcript for Prelude Therapeutics Incorporated's latest earnings report can be read online.
-
How much profit does Prelude Therapeutics Incorporated generate each year?
Prelude Therapeutics Incorporated (:PRLD) has a recorded net income of $0. Prelude Therapeutics Incorporated has generated $-2.02 earnings per share over the last four quarters.
-
What is Prelude Therapeutics Incorporated's price-to-earnings ratio?
Prelude Therapeutics Incorporated (:PRLD) has a price-to-earnings ratio of -0.55 and price/earnings-to-growth ratio is -0.5.
